Midazolam lactate | 90509-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: Midazolam lactate
• 英文别名: 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine;2-hydroxypropanoic acid
• CAS: 90509-04-9
• 化学式: C21H19ClFN3O3
• 分子量: 415.8
• InChiKey: ABRFMCOREJRKEK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.78
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• PHARMACEUTICAL COMPOSITIONS COMPRISING MIDAZOLAM IN A HIGH CONCENTRATION
  申请人：Merkus, Franciscus Wilhelmus Henricus Maria

  公开号：EP1703896A2

  公开（公告）日：2006-09-27
• INTRANASAL FORMULATION
  申请人：Cipla Limited

  公开号：EP3897577A1

  公开（公告）日：2021-10-27
• Pharmaceutical compositions comprising midazolam in a high concentration
  申请人：Merkus Henricus Maria Franciscus Wilhelmus

  公开号：US20050153956A1

  公开（公告）日：2005-07-14

  Compositions of midazolam, a benzodiazapine, in concentrations of 35-100 mg/ml are disclosed for the treatment of anxiety, epilepsy and epileptic seizures, invasive surgical procedures and diagnostic procedures and sedation. These compositions are particularly characterized by a solubilizer such an propylene glycol. Preferably, the compositions are aqueous solutions for intranasal administration.
• Intranasal Formulation
  申请人：CIPLA LIMITED

  公开号：US20210379080A1

  公开（公告）日：2021-12-09

  The present invention relates to the formulation of midazolam. In particular, the invention provides new midazolam formulation for intranasal administration. These formulations contain midazolam in a high concentration from about 1% to about 10% w/w of the formulation and process of preparation thereof.
• US7700588B2
  申请人：——

  公开号：US7700588B2

  公开（公告）日：2010-04-20